JP2012519712A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012519712A5 JP2012519712A5 JP2011553163A JP2011553163A JP2012519712A5 JP 2012519712 A5 JP2012519712 A5 JP 2012519712A5 JP 2011553163 A JP2011553163 A JP 2011553163A JP 2011553163 A JP2011553163 A JP 2011553163A JP 2012519712 A5 JP2012519712 A5 JP 2012519712A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- seq
- antibody
- sugar chain
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000009472 formulation Methods 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 13
- 238000000034 method Methods 0.000 claims 6
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 5
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims 5
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 5
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims 5
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 5
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims 5
- 229930182474 N-glycoside Natural products 0.000 claims 5
- 229950006780 n-acetylglucosamine Drugs 0.000 claims 5
- 208000037914 B-cell disorder Diseases 0.000 claims 4
- 239000013011 aqueous formulation Substances 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000001589 lymphoproliferative effect Effects 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15815309P | 2009-03-06 | 2009-03-06 | |
| US61/158,153 | 2009-03-06 | ||
| PCT/US2010/026492 WO2010102276A2 (en) | 2009-03-06 | 2010-03-08 | Humanized anti-cd19 antibody formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012519712A JP2012519712A (ja) | 2012-08-30 |
| JP2012519712A5 true JP2012519712A5 (enExample) | 2013-05-02 |
Family
ID=42710248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011553163A Withdrawn JP2012519712A (ja) | 2009-03-06 | 2010-03-08 | ヒト化抗ｃｄ１９抗体製剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20120148576A1 (enExample) |
| EP (1) | EP2403532A4 (enExample) |
| JP (1) | JP2012519712A (enExample) |
| KR (1) | KR20110125664A (enExample) |
| CN (1) | CN102413839A (enExample) |
| AU (1) | AU2010221099A1 (enExample) |
| BR (1) | BRPI1013237A2 (enExample) |
| CA (1) | CA2754266A1 (enExample) |
| MX (1) | MX2011009312A (enExample) |
| RU (1) | RU2011140486A (enExample) |
| WO (1) | WO2010102276A2 (enExample) |
| ZA (1) | ZA201106480B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101462693B1 (ko) * | 2006-08-16 | 2014-11-17 | 노파르티스 아게 | 고도 결정질 치료용 화합물의 고체 분산체 제조 방법 |
| UY32560A (es) | 2009-04-29 | 2010-11-30 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| MY161534A (en) * | 2010-05-25 | 2017-04-28 | Genentech Inc | Methods of purifying polypeptides |
| US20130195851A1 (en) * | 2011-12-23 | 2013-08-01 | Genentech, Inc. | Articles of manufacture and methods for co-administration of antibodies |
| WO2013138244A2 (en) * | 2012-03-12 | 2013-09-19 | Medimmune, Llc | Treatment of multiple sclerosis with anti-cd19 antibody |
| EP2841128A4 (en) * | 2012-04-23 | 2015-11-25 | Zogenix Inc | PISTON CLOSURES FOR MEDICINAL PACKAGING CAPSULES |
| BR112015000657B1 (pt) * | 2012-07-13 | 2023-12-05 | The Trustees Of The University Of Pennsylvania | Uso de uma célula geneticamente modificada para expressar um car |
| AU2013201465B2 (en) * | 2012-10-24 | 2016-03-03 | Rayner Intraocular Lenses Limited | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
| BR112015022210A8 (pt) * | 2013-03-13 | 2018-01-23 | Genentech Inc | formulações de anticorpo |
| SG11201607306PA (en) * | 2014-04-07 | 2016-09-29 | Seattle Genetics Inc | Stable formulations for anti-cd19 antibodies and antibody-drug conjugates |
| US10206878B2 (en) * | 2014-05-28 | 2019-02-19 | Nono Inc. | Lyophilized formulation of TAT-NR2B9C with acetylation scavenger |
| JP7072384B2 (ja) | 2014-09-15 | 2022-05-20 | ジェネンテック， インコーポレイテッド | 抗体製剤 |
| TWI809304B (zh) | 2014-12-01 | 2023-07-21 | 奥默羅斯公司 | 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液 |
| US11091543B2 (en) | 2015-05-07 | 2021-08-17 | Swedish Orphan Biovitrum Ag | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications |
| CA2985001A1 (en) | 2015-05-07 | 2016-11-10 | Novimmune Sa | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers |
| AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
| WO2017015783A1 (en) * | 2015-07-24 | 2017-02-02 | Shanghai Sidansai Biotechnology Co., Ltd | Humanized anti-cd19 antibody and use thereof |
| US10493139B2 (en) | 2015-07-24 | 2019-12-03 | Innovative Cellular Therapeutics CO., LTD. | Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor |
| SG11201810429UA (en) * | 2016-06-27 | 2018-12-28 | Morphosys Ag | Anti-cd19 antibody formulations |
| EP3330289A1 (en) * | 2016-12-02 | 2018-06-06 | Friedrich-Alexander-Universität Erlangen-Nürnberg | A cd33-, cd16- and cd123-specific single chain triplebody |
| KR20230144110A (ko) | 2017-03-02 | 2023-10-13 | 제넨테크, 인크. | Her2-양성 유방암 어쥬번트 치료 |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| SG11201909955XA (en) | 2017-05-02 | 2019-11-28 | Merck Sharp & Dohme | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
| CN110945028B (zh) | 2017-07-10 | 2023-09-08 | 国际药物发展生物技术公司 | 用非岩藻糖基化促凋亡抗cd19抗体与抗cd20抗体或化疗剂联合治疗b细胞恶性肿瘤 |
| CA3083936C (en) * | 2017-12-06 | 2022-08-23 | Abclon Inc. | Anti-cd19 antibody or antigen-binding fragment and cd19-specific chimeric antigen receptor comprising the same |
| EP3876990A4 (en) | 2018-11-07 | 2023-09-06 | Merck Sharp & Dohme LLC | CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
| MX2021009851A (es) | 2019-02-18 | 2021-09-10 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos. |
| SG11202111429UA (en) * | 2019-04-24 | 2021-11-29 | Viela Bio Inc | Use of an anti-cd19 antibody to treat autoimmune disease |
| WO2021067598A1 (en) | 2019-10-04 | 2021-04-08 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant aav |
| KR20220092578A (ko) * | 2019-11-05 | 2022-07-01 | 브리스톨-마이어스 스큅 컴퍼니 | M-단백질 검정 및 이의 용도 |
| WO2022026914A1 (en) * | 2020-07-31 | 2022-02-03 | Alamab Therapeutics, Inc. | Anti-connexin antibody formulations |
| KR20230127292A (ko) * | 2020-12-30 | 2023-08-31 | 아이-맵 바이오파마 컴파니 리미티드 | 항-cd73 항체의 제제 |
| WO2022223028A1 (zh) * | 2021-04-23 | 2022-10-27 | 上海君实生物医药科技股份有限公司 | 抗BLyS抗体、其药物组合物及其用途 |
| CN113208810B (zh) * | 2021-05-18 | 2022-04-12 | 南方医科大学深圳医院 | 一种用于smile术透镜染色低温分离液的超声波给药装置 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| EP1648512A4 (en) * | 2003-07-31 | 2009-01-21 | Immunomedics Inc | ANTI-CD19 ANTIBODIES |
| CN103694349A (zh) * | 2006-09-08 | 2014-04-02 | 米迪缪尼有限公司 | 人源化抗cd19抗体及其在治疗癌症、移植病和自身免疫病中的应用 |
-
2010
- 2010-03-08 RU RU2011140486/15A patent/RU2011140486A/ru unknown
- 2010-03-08 CN CN2010800197310A patent/CN102413839A/zh active Pending
- 2010-03-08 JP JP2011553163A patent/JP2012519712A/ja not_active Withdrawn
- 2010-03-08 CA CA2754266A patent/CA2754266A1/en not_active Abandoned
- 2010-03-08 WO PCT/US2010/026492 patent/WO2010102276A2/en not_active Ceased
- 2010-03-08 BR BRPI1013237A patent/BRPI1013237A2/pt not_active IP Right Cessation
- 2010-03-08 KR KR1020117023323A patent/KR20110125664A/ko not_active Withdrawn
- 2010-03-08 MX MX2011009312A patent/MX2011009312A/es not_active Application Discontinuation
- 2010-03-08 AU AU2010221099A patent/AU2010221099A1/en not_active Abandoned
- 2010-03-08 US US13/254,656 patent/US20120148576A1/en not_active Abandoned
- 2010-03-08 EP EP10749432A patent/EP2403532A4/en not_active Withdrawn
-
2011
- 2011-09-05 ZA ZA2011/06480A patent/ZA201106480B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012519712A5 (enExample) | ||
| CN110418803B (zh) | 抗rsv单克隆抗体配制品 | |
| ES2552954T3 (es) | Anticuerpos anti-C5a y métodos para el uso de los anticuerpos | |
| RU2011140486A (ru) | Композиции, содержащие гуманизированные антитела к cd19 | |
| TWI633891B (zh) | 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法 | |
| RU2012131099A (ru) | Препарат антитела | |
| RU2016129113A (ru) | Антитела к pd-1 собак | |
| JP2019527678A5 (enExample) | ||
| KR20200123170A (ko) | B7-h4 항체 제형 | |
| US20140072559A1 (en) | Highly concentrated aqueous protein solution with reduced viscosity | |
| AU2018244276A1 (en) | Methods and compositions for reduction of immunogenicity | |
| TW201406398A (zh) | 醫藥調配物 | |
| US20250136706A1 (en) | Methods For Prevention Of Graft Rejection In Xenotransplantation | |
| JP2022513350A (ja) | がんの併用療法 | |
| JP2006528627A5 (enExample) | ||
| JP2023516195A (ja) | Ｃ１９ ｃ３８二特異性抗体 | |
| TWI726426B (zh) | 包含抗ｏｘ４０抗體的製劑、其製備方法及其用途 | |
| TW202508630A (zh) | 治療表現ｃｄ２０之ｂ細胞癌症之方法 | |
| TW202021620A (zh) | 一種cd40抗體藥物組合物及其用途 | |
| TW202034925A (zh) | Ｃｄｋ４／６抑制劑聯合免疫治療在製備治療淋巴瘤的藥物中的用途 | |
| AU2024274503A9 (en) | Methods of treating cd20 expressing b-cell cancers | |
| TWI895541B (zh) | 包含抗原和其醣工程化抗體之免疫組合物 | |
| HK40011725B (zh) | 抗rsv单克隆抗体配制品 | |
| HK40011725A (en) | Anti-rsv monoclonal antibody formulation | |
| HK40002161A (en) | Anti-rsv monoclonal antibody formulation |